25th Apr 2022 08:32
(Alliance News) - AstraZeneca PLC on Monday announced its candidate for unresectable liver cancer Tremelimumab has been accepted under priority review by the US Food & Drug Administration.
Patients with unresectable liver cancer will receive the antibody in combination with AstraZeneca's immunotherapy Imfinzi, also known as Durvalumab, the Cambridge-based drugmaker said.
A phase III study with the two AstraZeneca products highlighted "the potential for this regimen to improve longer-term survival outcomes," explained Susan Galbraith, executive vice president of the oncology research & development arm of AstraZeneca.
AstraZeneca shares were 0.8% lower at 10,200.00 pence each in London on Monday morning.
By Tom Budszus; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca